Stealth CAR-Tregs evade CD3 antibody therapy and skew immune responses toward regulation
Tifanie Blein, Nicolas Ayas, Soëli Charbonnier, Artur Gil, Aness Haddouche, Jehanne Hassan, Lucas Rabaux, Isabelle Andre, Herman Waldmann, Baptiste Lamarthée, Makoto Miyara, Lucienne Chatenoud, Juliette Léon, Julien Zuber
This study shows that TRAC-/-CAR-Tregs survive CD3 antibody therapy better than TRAC+/+CAR-Tregs, shifting immune responses toward regulation.
bioRxiv · Oct 20, 2026 · PreprintImmunology